West Pharmaceutical Services (NYSE:WST) Releases FY 2026 Earnings Guidance

West Pharmaceutical Services (NYSE:WST) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 8.400-8.750 for the period, compared to the consensus estimate of 7.990. The company issued revenue guidance of $3.3 billion-$3.4 billion, compared to the consensus revenue estimate of $3.2 billion. West Pharmaceutical Services also updated its Q2 2026 guidance to 2.050-2.120 EPS.

West Pharmaceutical Services Trading Up 12.7%

Shares of WST stock opened at $309.25 on Friday. West Pharmaceutical Services has a 12-month low of $199.89 and a 12-month high of $322.34. The company has a current ratio of 3.02, a quick ratio of 2.34 and a debt-to-equity ratio of 0.06. The firm’s 50 day moving average is $252.00 and its 200 day moving average is $262.10. The stock has a market capitalization of $22.29 billion, a P/E ratio of 45.54, a P/E/G ratio of 2.92 and a beta of 1.15.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings results on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share for the quarter, topping the consensus estimate of $1.68 by $0.45. The business had revenue of $844.90 million for the quarter, compared to analysts’ expectations of $779.68 million. West Pharmaceutical Services had a net margin of 16.06% and a return on equity of 17.90%. The company’s revenue was up 21.0% compared to the same quarter last year. During the same quarter last year, the company posted $1.45 EPS. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. Research analysts expect that West Pharmaceutical Services will post 7.91 earnings per share for the current year.

West Pharmaceutical Services Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 6th. Stockholders of record on Wednesday, April 29th will be given a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Wednesday, April 29th. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 12.96%.

West Pharmaceutical Services announced that its Board of Directors has approved a stock buyback plan on Tuesday, February 17th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the medical instruments supplier to repurchase up to 5.6% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s board of directors believes its shares are undervalued.

Analyst Upgrades and Downgrades

WST has been the topic of a number of research reports. UBS Group reiterated a “buy” rating and issued a $340.00 price target on shares of West Pharmaceutical Services in a report on Friday, February 13th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $315.00 price target on shares of West Pharmaceutical Services in a report on Friday, February 13th. Evercore reduced their price target on shares of West Pharmaceutical Services from $390.00 to $320.00 and set an “outperform” rating on the stock in a report on Tuesday, February 3rd. Zacks Research downgraded shares of West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a report on Tuesday, April 14th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of West Pharmaceutical Services in a report on Friday, January 9th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $315.67.

Key Headlines Impacting West Pharmaceutical Services

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: Q1 beat and strong operating performance: West reported Q1 EPS of $2.13 vs. consensus ~$1.68 and revenue of $844.9M (?+21% YoY). Management cited margin expansion and solid returns. PR Newswire Q1 Release
• Positive Sentiment: Raised guidance: West lifted FY?2026 EPS to $8.40–$8.75 (above Street) and Q2 EPS to $2.05–$2.12, and increased revenue outlook to $3.3–$3.4B — signaling confidence in demand and pricing. Reuters: Forecast Lift
• Positive Sentiment: Product mix & HVP growth driving upside: Management and coverage note strong demand for higher?value packaging components (syringes, cartridges, packaging) that are boosting revenues and margins. Analysts raised EPS views on HVP momentum. Zacks: HVP Growth
• Neutral Sentiment: Analyst and market reaction: Multiple outlets summarized the quarterly call and analysts have updated models; slides and the conference call are available for deeper detail — useful for confirming sustainability of growth drivers. MarketBeat: Call/Slides
• Negative Sentiment: Valuation and positioning risk: WST trades at a premium (P/E ~45) and near its 12?month high, which could limit upside or increase volatility if organic growth or margin expansion slows. Seeking Alpha: Market Reaction

Institutional Investors Weigh In On West Pharmaceutical Services

Several large investors have recently added to or reduced their stakes in WST. Generation Investment Management LLP raised its holdings in shares of West Pharmaceutical Services by 60.0% in the 4th quarter. Generation Investment Management LLP now owns 1,561,869 shares of the medical instruments supplier’s stock valued at $429,733,000 after purchasing an additional 585,855 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its holdings in shares of West Pharmaceutical Services by 67.5% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,174,962 shares of the medical instruments supplier’s stock valued at $323,280,000 after purchasing an additional 473,547 shares in the last quarter. Steadfast Capital Management LP bought a new stake in shares of West Pharmaceutical Services in the 3rd quarter valued at about $123,667,000. AQR Capital Management LLC raised its holdings in shares of West Pharmaceutical Services by 420.1% in the 3rd quarter. AQR Capital Management LLC now owns 545,879 shares of the medical instruments supplier’s stock valued at $142,949,000 after purchasing an additional 440,929 shares in the last quarter. Finally, Viking Global Investors LP bought a new stake in shares of West Pharmaceutical Services in the 4th quarter valued at about $81,174,000. 93.90% of the stock is owned by hedge funds and other institutional investors.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.